Informations générales (source: ClinicalTrials.gov)
Diagnostic Ability of Diffusion MRI and Diffusion Tensor in Renal Graft Biopsies: Pilot Study
Interventional
N/A
CHU de Reims (Voir sur ClinicalTrials)
avril 2014
décembre 2017
29 juin 2024
While renal graft outcomes were really improved for the last decade, long time outcomes
remains stable. Indeed, at 10 years after transplantation, the renal graft survival rate
reaches 50%. The chronic allograft nephropathy is the main cause of renal graft loss.
Other features such as acute allograft rejection, delayed renal recovery and anti-human
leukocyte antigen (anti-HLA) antibodies are associated with poor renal graft survival
prognosis. Renal graft protocol biopsies at 3 and 12 months after transplantation are
valuable to detect precociously renal injuries at a reversible stage before clinical
manifestation. However, renal biopsy is an invasive examination with hemorrhagic risk.
Diffusion MRI could be a non-invasive diagnostic tool allowing the early detection of
renal injuries, especially allograft rejection without hemorrhagic risk. This tool could
be applied routinely to the renal allograft recipient in replacement of protocol
biopsies.
Here, aim of this study is to correlate the results from diffusion MRI of renal graft
with pathologic findings from protocol renal graft biopsies.
In this view, the investigators include prospectively all recipients of renal
transplantation who beneficiate of a protocol renal graft biopsy without barrier to
peform MRI examination. Thus, the investigators exclude patients who are not be able to
beneficiate of a MRI examination and patient obstacle to renal graft biopsy.
Expected results are the Banff classification from the histopathologic analysis of
biopsies. The expected results for MRI examination are signal intensity, diffusive
coefficient, anisotropy fraction and change of the diffusion way. Next, the investigators
search an association between these features by statistical analysis (Wilcoxon test,
Chi², Fisher, Pearson or Spearman).
The investigators performed this study since 01/06/2014 and projected end-time to
01/06/2017.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Chu de Reims - 51092 - Reims - France | Vincent VUIBLET | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Renal graft recipient from Reims hospital
- Over 18 years
- With consent
- Renal graft recipient from Reims hospital
- Over 18 years
- With consent
- None